Acknowledgement
The authors thank all patients and investigators who participated in this study. We also thank Roche, Ltd. (Korea) for supplying the capecitabine.
References
- Faivre J, Forman D, Esteve J, Gatta G; EUROCARE Working Group. Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 1998;34:2167-2175. https://doi.org/10.1016/S0959-8049(98)00329-3
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. https://doi.org/10.3322/caac.21254
- Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 2019;30:19-33. https://doi.org/10.1093/annonc/mdy502
- Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008;99:1402-1407. https://doi.org/10.1038/sj.bjc.6604732
- Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. https://doi.org/10.1056/NEJMoa073149
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221. https://doi.org/10.1016/S1470-2045(08)70035-4
- Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, et al. Real-world treatment patterns among patients with advanced gastric cancer in South Korea. Cancer Res Treat 2017;49:578-587. https://doi.org/10.4143/crt.2016.001
- Eren OO, Ozturk MA, Sonmez OU, Oyan B. Safety, feasibility, and efficacy of capecitabine maintenance in patients with advanced gastric cancer: a retrospective study. Am J Ther 2016;23:e1493-e1497. https://doi.org/10.1097/MJT.0000000000000156
- Qiu MZ, Wei XL, Zhang DS, Jin Y, Zhou YX, Wang DS, et al. Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. Tumour Biol 2014;35:4369-4375. https://doi.org/10.1007/s13277-013-1574-5
- Yao Y, Deng R, Liao D, Xie H, Zuo J, Jia Y, et al. Maintenance treatment in advanced HER2-negative gastric cancer. Clin Transl Oncol 2020;22:2206-2212. https://doi.org/10.1007/s12094-020-02379-7
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21. https://doi.org/10.1007/s10120-020-01042-y
- Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 2008;61:623-629. https://doi.org/10.1007/s00280-007-0515-7
- Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. https://doi.org/10.1111/j.1365-2559.2008.03028.x
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
- Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 2012;48:554-559. https://doi.org/10.1016/j.oraloncology.2012.01.004
- Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 1988;44:229-241. https://doi.org/10.2307/2531910
- Shitara K, Ikeda J, Yokota T, Takahari D, Ura T, Muro K, et al. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs 2012;30:1224-1231. https://doi.org/10.1007/s10637-011-9648-y
- Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-5733. https://doi.org/10.1200/JCO.2009.23.4344
- Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, et al. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer Chemother Pharmacol 2011;67:1111-1117. https://doi.org/10.1007/s00280-010-1322-0
- Roviello G, Rodriquenz MG, Aprile G, D'Angelo A, Roviello F, Nobili S, et al. Maintenance in gastric cancer: new life for an old issue? Crit Rev Oncol Hematol 2021;160:103307.
- Petrioli R, Francini E, Roviello F, Marrelli D, Miano ST, Fiaschi AI, et al. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status. J Geriatr Oncol 2015;6:380-386. https://doi.org/10.1016/j.jgo.2015.06.002
- Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer 2017;83:32-42. https://doi.org/10.1016/j.ejca.2017.06.008
- Lu B, Bao LB, Sun Z, Hua ZL, Wang X, Qu CP. Efficacy and safety of capecitabine as maintenance therapy after capecitabine-based combination chemotherapy for patients with advanced esophagogastric junction adenocarcinoma. Eur Rev Med Pharmacol Sci 2015;19:3605-3612.
- Haag GM, Stocker G, Quidde J, Jaeger D, Lordick F. Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study. BMC Cancer 2017;17:509.
- Haag GM, Stocker G, Lorenzen S, Ettrich TJ, Longo F, Kiani A, et al. 1447P S-1 maintenance therapy in non-Asian patients with advanced, HER-2 negative esophagogastric adenocarcinoma - first results of the international MATEO trial initiated by the AIO. Ann Oncol 2020;31:S910.
- Moehler M, Dvorkin M, Boku N, Ozguroglu M, Ryu MH, Muntean AS, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol 2021;39:966-977. https://doi.org/10.1200/JCO.20.00892